Prevalence of skin cancer in Native American kidney transplant recipients

Ilyas, Muneeb; Ginsberg, Zachary; Temkit, Mʼhamed; Keddis, Mira T.; Sharma, Amit

doi:10.1111/ijd.13863

Cited by 6 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Racial differences in malignancy risk after KTx has been identified for Black and Hispanic recipients but has not been reported for the Indigenous patients post-transplant outside of skin [22]. The risk for malignancy in our cohort was significantly lower among the Indigenous patients and there were no cases of skin malignancy in that cohort which is consistent with known decreased prevalence of skin cancer in Indigenous KTx recipients compared to Whites after transplant [23]. The increase in malignancy risk after KTx has been partly attributed to baseline risk and in our study the White cohort had significantly higher rates of malignancy prior to KTx and after KTx consistent with current literature [22].…”

Section: Plos Onesupporting

confidence: 83%

Patient and allograft outcomes after kidney transplant for the Indigenous patients in the United States

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background The objective is to assess cardiovascular (CV), malignancy, infectious, graft outcomes and tacrolimus levels for the Indigenous patients compared to Whites after kidney transplant (KTx). Methods 165 Indigenous and 165 White patients matched for the KTx year at Mayo Clinic Arizona from 2007–2015 were studied over a median follow-up of 3 years. Propensity score was calculated to account for baseline differences. Results Compared to Whites, Indigenous patients had the following characteristics: younger age, more obesity, diabetes, hypertension, and required dialysis prior to KTx (p<0.01). Indigenous patients had longer hospital stay for KTx, shorter follow-up and lived further from the transplant center (p<0.05). 210 (63.6%) received deceased donor KTx and more Whites received a living donor KTx compared to Indigenous patients (55.2% vs 17.6%, p<0.0001). Post-KTx, there was no difference in the CV event rates. The cumulative incidence of infectious complications was higher among the Indigenous patients (HR 1.81, p = 0.0005, 48.5% vs 38.2%, p = 0.013), with urinary causes as the most common. Malignancy rates were increased among Whites (13.3% vs 3.0%, p = 0.001) with skin cancer being the most common. There was a significant increase in the dose normalized tacrolimus level for the Indigenous patients compared to Whites at 1 months, 3 months, and 1 year post-KTx. After adjustment for the propensity score, there was no statistical difference in infectious or graft outcomes between the two groups but the mean number of emergency room visits and hospitalizations after KTx was significantly higher for Whites compared to Indigenous patients. Conclusions Compared to Whites, Indigenous patients have similar CV events, graft outcomes and infectious complications after accounting for baseline differences.

show abstract

Section: Plos Onesupporting

confidence: 83%

Patient and allograft outcomes after kidney transplant for the Indigenous patients in the United States

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Notably, over the past five years, some follow-up studies have found lower BCC:SCC ratios. 20,24,25 These results can be partially explained by the reduced trend of SCC incidence over the past 20 years in solid organ transplant recipients. 26,27 This decline is likely caused by less aggressive and more individualized immunosuppression therapy.…”

Section: Discussionmentioning

confidence: 99%

Frequency of skin diseases in renal transplant recipients and patients with chronic kidney disease in a tertiary center: a cross-sectional study

Vieira,

Marcolino,

Guedes

et al. 2024

Sao Paulo Med. J.

View full text Add to dashboard Cite

INTRODUCTIONChronic kidney disease (CKD) is a significant global public health problem with a major socioeconomic impact. 1,2 Its worldwide prevalence is estimated at 10-16%; 1,3,4 additionally, its prevalence has increased in the recent decades, along with the number of patients with terminal CKD requiring transplantation, 3,6 mostly due to the increase in the prevalence of hypertension and diabetes mellitus. 4,5 Patients with CKD are prone to skin abnormalities. 7,8 These manifestations are often associated with impaired renal function and are more prevalent in end-stage disease, 7,8 when the kidneys are unable to maintain appropriate levels of metabolic products, such as urea, creatinine, sodium, calcium, and phosphate, causing damage to several organs, including the skin. 9 Kidney transplantation is the best treatment for patients with end-stage CKD; 3,10 however, the immunosuppression required to maintain the graft can lead to various side effects and a greater susceptibility to infectious and neoplastic diseases. 11 Besides immunosuppression itself, the mechanisms of action of immunosuppressive drugs and viral infections (oncogenic viruses) are associated with cutaneous disorders in renal transplant recipients (RTR). 12,13

show abstract

“…There were two patients with squamous cell carcinoma (both Brigham and Women's Hospital T2a; one American Joint Committee on Cancer 8 th edition T2 and one T3) on immunosuppression due to kidney transplant and neither patient had a prior history of skin cancer or experienced recurrence. A study evaluating the prevalence of skin cancer in Native Americans kidney transplant recipients concluded that rates of skin cancer in Native Americans solid organ transplant patients seem to be much lower compared to White recipients [7].…”

Section: Discussionmentioning

confidence: 99%

“…There is scarce literature on skin cancers in Native Americans, who represent approximately 1.3% of the total population [6]. Previous studies have estimated non-melanoma skin cancer incidence of 2% in Native Americans [7] compared to 20-30% in Whites in the U.S. [3]. Data regarding non-melanoma skin cancer characteristics, treatment outcome, and mortality in Native Americans populations is lacking.…”

Section: Introductionmentioning

confidence: 99%

Characteristics of non-melanoma skin cancers in Native American patients treated with Mohs micrographic surgery

Tchanque-Fossuo¹,

Ravichandran²,

Barbosa³

2022

DOJ

View full text Add to dashboard Cite

Prevalence of skin cancer in Native American kidney transplant recipients

Abstract: NAKTRs have a decreased prevalence of skin cancer compared to their white counterparts.

Cited by 6 publications

References 14 publications

Patient and allograft outcomes after kidney transplant for the Indigenous patients in the United States

Patient and allograft outcomes after kidney transplant for the Indigenous patients in the United States

Frequency of skin diseases in renal transplant recipients and patients with chronic kidney disease in a tertiary center: a cross-sectional study

Characteristics of non-melanoma skin cancers in Native American patients treated with Mohs micrographic surgery

Contact Info

Product

Resources

About